Talimogene laherparepvec: First in class oncolytic virotherapy

Chronic granulomatous dermatitis induced by talimogene laherparepvec therapy of melanoma metastases

(2017) Ashlyn S. Everett et al.   JOURNAL OF CUTANEOUS PATHOLOGY

Oncolytic Virotherapy: A Contest between Apples and Oranges

(2017) Stephen J. Russell et al.   MOLECULAR THERAPY

Review: Oncolytic virotherapy, updates and future directions

(2017) Christos Fountzilas et al.   Oncotarget

Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma

(2016) Praveen K. Bommareddy et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma

(2016) Robert H. I. Andtbacka et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial

(2016) Kevin Harrington et al.   OncoTargets and Therapy

Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy

(2015) F. J. Kohlhapp et al.   CLINICAL CANCER RESEARCH

Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma

(2015) Douglas B Johnson et al.   Immunotherapy

Society for Melanoma Research 2015 Congress

(2015)   Pigment Cell & Melanoma Research

Pembrolizumab

(2015) Leila Khoja et al.   Journal for ImmunoTherapy of Cancer

Biosafety of Gene Therapy Vectors Derived From Herpes Simplex Virus Type 1

(2014) Filip Lim et al.   CURRENT GENE THERAPY

Ipilimumab Plus Sargramostim vs Ipilimumab Alone for Treatment of Metastatic Melanoma

(2014) F. Stephen Hodi et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

CTLA-4 and PD-L1 Checkpoint Blockade Enhances Oncolytic Measles Virus Therapy

(2014) Christine E Engeland et al.   MOLECULAR THERAPY

Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy

(2014) D. Zamarin et al.   Science Translational Medicine

Diagnosis of genital herpes simplex virus infection in the clinical laboratory

(2014) Jérôme LeGoff et al.   Virology Journal

Current status of granulocyte–macrophage colony-stimulating factor in the immunotherapy of melanoma

(2014) Howard L Kaufman et al.   Journal for ImmunoTherapy of Cancer

Optimizing patient derived mesenchymal stem cells as virus carriers for a Phase I clinical trial in ovarian cancer

(2013) Emily K Mader et al.   Journal of Translational Medicine

Differing Patterns of Circulating Regulatory T Cells and Myeloid-derived Suppressor Cells in Metastatic Melanoma Patients Receiving Anti-CTLA4 Antibody and Interferon-α or TLR-9 Agonist and GM-CSF With Peptide Vaccination

(2012) Ahmad A. Tarhini et al.   JOURNAL OF IMMUNOTHERAPY

Phase I/II Study of Oncolytic HSVGM-CSF in Combination with Radiotherapy and Cisplatin in Untreated Stage III/IV Squamous Cell Cancer of the Head and Neck

(2010) K. J. Harrington et al.   CLINICAL CANCER RESEARCH

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Local and Distant Immunity Induced by Intralesional Vaccination with an Oncolytic Herpes Virus Encoding GM-CSF in Patients with Stage IIIc and IV Melanoma

(2009) Howard L. Kaufman et al.   ANNALS OF SURGICAL ONCOLOGY

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

(2009) J. D. Wolchok et al.   CLINICAL CANCER RESEARCH

Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma

(2009) Neil N. Senzer et al.   JOURNAL OF CLINICAL ONCOLOGY